AI assistant
PULSE BIOSCIENCES, INC. — Director's Dealing 2020
Jun 25, 2020
32093_dirs_2020-06-25_5e449906-588d-498b-b150-2961e9fb4e12.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Pulse Biosciences, Inc. (PLSE)
CIK: 0001625101
Period of Report: 2020-06-23
Reporting Person: Zanganeh Maky (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-06-23 | Common Stock | P | 1193 | $10.7017 | Acquired | 106767 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 352500 | Direct |
| Common Stock | 27000 | Indirect |
| Common Stock | 14000 | Indirect |
Footnotes
F1: The Reporting Person's immediate family member received the shares from a banking institution as resolution to an error made by the institution in connection with a subscription order placed for the Issuer's rights offering. Such shares were not acquired directly from the Issuer.
F2: This is the weighted average purchase price of the shares, which ranged from $10.69 to $10.73 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares purchased at each separate price within the range set forth in this Form 4.